Search results
PROMOTED
How do worsening heart events dictate the long-term outcomes of patients with transthyretin amyloid cardiomyopathy (ATTR-CM) and can earlier intervention influence the disease trajectory in ATTR-CM? In this new sub-analysis from ATTRibute-CM, recorded onsite at ESC Heart Failure Congress (HFA) 2026, Prof Marianna Fontana (University College London, London, UK) sheds further light onto these…
View more
HFA 2026: Updates on ATTR-CM
Added:
4 days ago
Video Series
Treatment Options and Continuity of Care in MAFLD
Added:
1 year ago
Review Article
Resistant Hypertension: An Overview
Added:
1 year ago
Review Article
AHA 24: The OPTION Trial
Added:
1 year ago
Video
Start date:
Sep 11, 2024
Join us for an unparalleled educational journey dedicated to tackling the complexities of managing HFpEF and HFmrEF patients. This CME-accredited live roundtable is chaired by Dr Biykem Bozkurt (Baylor College of Medicine, US) and features insights from renowned experts Prof Pardeep Jhund (University of Glasgow, UK) and Dr Muthiah Vaduganathan (Brigham and Women’s Hospital and Harvard Medical…
View more
Added:
8 months ago
Discover the rapidly evolving therapeutic options transforming outcomes for cardiac amyloidosis patients with Dr Sarah Cuddy.This comprehensive presentation, part of the Cardiomyopathies track, explores the dramatic advances in both TTR and AL amyloidosis treatment over the past decade. Dr Cuddy examines how modern therapeutic approaches have fundamentally shifted survival curves, particularly…
View more
Added:
8 months ago
ESC Congress 2025 - New guidelines for catheter-based VTE therapy emphasise the importance of involving vascular experts, and performing procedures in experienced centers.Dr Oliver Schlager (Medical University of Vienna, AT) joins us to discuss the newly released 2025 ESVM Guidelines on Interventional Treatment of Venous Thromboembolism, endorsed by European national societies of Vascular…
View more
Added:
8 months ago
Presented at the European Society of Cardiology (ESC) Congress 2025, Prof Carolyn Lam (Singapore, UK), Prof Davide Capodanno (Catania, IT), Dr Sneha Shah Jain (Stanford, US) and Prof Jeffrey Weitz (Hamilton, CA) examine the prevalence and challenges of stroke prevention in atrial fibrillation (AF) and after acute coronary syndrome (ACS). The faculty review current treatment guidelines, explore…
View more
Added:
7 months ago
Navigate the rapidly evolving treatment landscape for hypertrophic cardiomyopathy with Dr Anjali Tiku Owens, a renowned expert in inherited cardiovascular diseases and advanced heart failure.This comprehensive presentation, part of the Cardiomyopathies track of Women As One's CLIMB® 2025 Skills Training Program, explores both established and emerging therapeutic approaches for obstructive and non…
View more
Added:
6 months ago
AHA Scientific Sessions 2025 - Dr Sarah Cuddy (Brigham and Women's Hospital, US) joins us to discuss the role of non-disease modifying treatments including SGLT2 inhibitors, mineralocorticoid receptor antagonists, GLP-1 receptor agonists, and implantable hemodynamic monitors in cardiac amyloidosis, and what this means for managing heart failure in this unique patient population.Interview…
View more